<DOC>
	<DOCNO>NCT02972528</DOCNO>
	<brief_summary>Allogenic defibrinate platelet rich plasma lysate inject patient diagnose Diabetic Foot Ulcer ( DFU ) .</brief_summary>
	<brief_title>The Use Allogenic Platelet Rich Plasma Treatment Diabetic Foot Ulcer</brief_title>
	<detailed_description>In study , allogenic , defibrinated platelet rich plasma lysate use direct injection periphery diabetic chronic foot ulcer heal use standard care . Investigators anticipate significant response treat individual measure percentage skin restoration achieve .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Persons type 1 type 2 diabetes age 18 70 ulcer least 4 week duration 2 . HemoglobinA1C ( HbA1c ) &lt; 12 3 . Index foot ulcer locate plantar , medial , lateral aspect foot ( include toe surface ) ; wind area ( length x width ) measurement 2 cm2 20 cm2 , inclusive . 4 . Wounds locate Charcot deformity free acute change must go appropriate structural consolidation . 5 . The index ulcer clinically noninfected full thickness without exposure bone , ligament , tendon . 6 . The protocol require post debridement ulcer would free necrotic debris , foreign body sinus tract . 7 . Non invasive vascular test ankle brachial index ( ABI ) . 8 . Physical examination ( include SemmesWeinstein monofilament test neuropathy ) 9 . Blood test obtain Complete Blood Count HbA1c . 10 . Approved , inform , sign consent . 11 . Negative test Hepatitis C ( HC ) , Hepatitis B ( HB ) , Human Immunodeficiency Virus 1 2 ( HIVI II ) , Venereal Disease Research Laboratory ( VDRL ) . 1 . Patient currently enrol another investigational device drug trial previously enrol ( within last 30 day ) investigative research device pharmaceutical agent . 2 . Ulcer decrease ≥50 % area 7day screening period . 3 . Ulcer due nondiabetic etiology . 4 . Patient 's blood vessel noncompressible ABI testing . 5 . Evidence gangrene ulcer part foot . 6 . Patient radiographic evidence consistent diagnosis acute Charcot foot . 7 . Patient currently receive receive radiation chemotherapy within 3 month randomization . 8 . Patient receive growth factor therapy within 7 day randomization . 9 . Screening hemoglobin &lt; 10.5 mg/dL . 10 . Screening platelet count &lt; 100 x 109/L . 11 . Patient undergoing renal dialysis , know immune insufficiency , know abnormal platelet activation disorder — ie , gray platelet syndrome , liver disease , active cancer ( except remote basal cell skin ) , eating/ nutritional , hematologic , collagen vascular disease , rheumatic disease , bleed disorder . 12 . History peripheral vascular repair within 30 day randomization 13 . Patient know suspect osteomyelitis . 14 . Surgical correction ( debridement ) require ulcer heal . 15 . Index ulcer expose tendon , ligament , muscle , bone . 16 . Patient known psychological , developmental , physical , emotional , social disorder , situation may interfere compliance study requirement and/or heal ulcer 17 . History alcohol drug abuse within last year prior randomization . 18 . Patient inadequate venous access blood draw . 19 . Positive test HC , HB , HIVI II , VDRL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DFU</keyword>
	<keyword>Diabetic Foot Ulcer</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Platelet Rich Plasma</keyword>
</DOC>